ロード中...
Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase 1 Trial
PURPOSE: This dose-finding phase 1 study investigated the maximum tolerated dose (MTD) and safety of weekly nab-rapamycin in patients with untreatable advanced nonhematologic malignancies. EXPERIMENTAL DESIGN: nab-Rapamycin was administered weekly for 3 weeks followed by 1 week of rest, with a start...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3935482/ https://ncbi.nlm.nih.gov/pubmed/24089446 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-3110 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|